



## **Piramal Pharma Solutions receives 'API Supplier of the Year' award at Global Generics and Biosimilar Award 2015**

**21st October, 2015:** Piramal Pharma Solutions (PPS), a division of Piramal Enterprises Limited, is pleased to announce that it is the recipient of the '**API Supplier of the Year**' award for 2015 **at Global Generics and Biosimilar Award**. This prestigious award, sponsored by Honeywell, Thomson Reuters, Panacea, Pharmawise, Pharmacloud, and Ark Patents, recognizes best business practices, and operational & R&D achievements in Global Generics and Biosimilars.

The Global Generics and Biosimilar awards are organized by Generics Bulletin, which has subscribers in over 60 countries. This year's nominations included over 100 global firms; the finalists, in addition to Piramal Pharma Solutions, included respected global leaders such as Divis, Johnson Matthey, Granules Pharma, and Neuland. Several well-known global leaders such as Actavis, Sandoz, Teva, Mylan, Apotex, Perrigo, DRL, Lupin, and Cipla were nominated in other categories.

**Vivek Sharma, CEO-Pharma Solutions, Piramal Enterprises** commented: "We are delighted and honoured by this recognition. This award is reflective of the pillars of quality, customer centricity, and operational excellence on which we operate. We respect that our clients have choices and that they choose Piramal with a certain expectation- from our end. We work towards delivering and continually improving on those expectations. This recognition reflects the commitment to excellence from the Piramal API team, and I am proud to work with them".

**Venkat Raman, President - API Generics, Pharma Solutions, Piramal Enterprises** added: "The award validates the energy and enthusiasm I see daily from the API team, be it operations, R&D, or in quality. It is nice to see our clients and peers also recognize this and choose us from among some excellent peer companies. We will do our best to focus on getting even better next year".

Piramal's state-of-the-art API business unit has manufacturing and R&D locations in North America, Europe, Asia; Piramal serves both blue chip pharma firms, and biotech. An active global R&D team focuses on innovation, and supports manufacturing locations

in Toronto (Canada), Morpeth (UK), Grangemouth (UK), Digwal and Ennore (India). By utilizing small, nimble, cross functional teams, Piramal has crafted elegant and cost effective solutions in a limited time, to high value chemistries that have presented challenges to clients.

**-ENDS-**

**About Piramal Enterprises Limited**

Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in Healthcare, Healthcare Information Management and Financial Services. PEL's consolidated revenues were over \$ 830 million in FY2015, with approx. 70% of revenues from outside India.

In healthcare, PEL is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India. The Molecular Imaging Division was formed in 2012 with presence in Europe and USA.

PEL's healthcare information management business, Decision Resources Group, is amongst the top 20 US market research organizations which provide information services to the healthcare industry.

In financial services, PEL, through its Piramal Fund Management Division, provides comprehensive financing solutions to real estate companies. The Structured Investment Group ("SIG") provides long term patient mezzanine growth capital to capital intensive businesses which are integral part of India's growth story. The total funds under management under these businesses are over \$ 2.5 billion. The company also has strategic alliances with top global pension funds like CPPIB Credit Investment Inc. and APG Asset Management. PEL also has long term equity investments worth over \$ 700 million in Shriram Group, a leading financial conglomerate in India.

PEL is listed on the Bombay Stock Exchange and the National Stock Exchange in India.

**For media enquiries, please contact:**

Akansha Pradhan  
Corporate Communications,  
Piramal Group  
Tel: +91 22 3351 4082  
[akansha.pradhan@piramal.com](mailto:akansha.pradhan@piramal.com)

**PUBLIC RELATIONS CONSULTANT:**

Alex Heeley, Partner, De Facto Communications  
+44 (0) 20 3735 8168  
[a.heeley@defacto.com](mailto:a.heeley@defacto.com)

**For Investors:**

Hitesh Dhaddha,  
Investor Relations Team,  
Piramal Enterprises Limited  
Tel: +91 (0) 22 6151 3430  
[investor.relations@piramal.com](mailto:investor.relations@piramal.com)